Ocuphire Pharma has initiated a phase 2 clinical trial investigating APX3330 in nonproliferative and mild proliferative diabetic retinopathy, according to a press release.
ZETA-1, a randomized, placebo-controlled, double-masked study, will investigate the efficacy of APX3330 over 24 weeks. The primary endpoint is the percentage of patients with a two or greater step improvement on the Diabetic Retinopathy Severity Scale. Secondary endpoints include an evaluation of central subfield thickness “to assess effects on diabetic macular edema, [best corrected visual acuity], safety and tolerability,”